Welcome to our dedicated page for Edesa Biotech SEC filings (Ticker: EDSA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Edesa Biotech filings document the formal disclosure record of a clinical-stage biotechnology issuer focused on host-directed therapeutics for immuno-inflammatory diseases. Recent Form 8-K reports cover clinical-study disclosures for paridiprubart in Acute Respiratory Distress Syndrome, operating and financial results, material-event updates and agreements connected to funded development work.
The company’s filings also address capital-structure matters, including common-share sales under at-the-market offering arrangements and related Form S-3 prospectus supplements. Proxy materials cover shareholder voting matters, board governance, executive compensation and equity-award disclosures for the public company.
Edesa Biotech, Inc. Schedule 13G shows a group of related filers including Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander reporting shared beneficial ownership of 520,685 shares, equal to 5.4% of the company’s common stock. The filing bases the percent on 9,621,192 Common Shares outstanding, composed of 8,891,951 shares as of May 13, 2026 and 729,241 shares issued in a private placement that closed on or about June 15, 2026. The filing is a joint filing under a Joint Filing Agreement dated June 17, 2026 and describes shared voting and dispositive power rather than sole control.
Dr. Pardeep Nijhawan has filed Amendment No. 10 to his Schedule 13D for Edesa Biotech, Inc., updating his ownership in the company’s common shares. As of June 16, 2026, he may be deemed the beneficial owner of 2,210,022 common shares, representing approximately 19.99% of Edesa’s outstanding common shares on an as‑converted, as‑exercised basis.
His position includes 927,620 shares over which he has sole voting and dispositive power, and 1,282,402 shares over which he has shared power through several affiliated entities. The amendment reflects multiple restricted stock unit grants in 2025–2026, open‑market purchases in March 2026, and a June 16, 2026 private placement purchase of 153,550 shares at $5.21 per share for a total of $799,995.50.
The filing notes a 19.99% beneficial ownership blocker on certain Series B‑1 preferred shares, which limits further conversions that would push his ownership above that threshold.
Edesa Biotech, Inc. Chief Executive Officer Pardeep Nijhawan acquired additional common shares in a private transaction. On June 16, 2026, he purchased 153,550 common shares at $5.21 per share, for a total of $799,995.50, and now directly holds 884,684 common shares.
He also has indirect holdings through several entities and a family trust, where he disclaims beneficial ownership beyond his pecuniary interest. These structures mean some shares are legally held by corporations and a trust associated with him rather than in his own name.
Edesa Biotech, Inc. entered into a securities purchase agreement for a private placement of approximately $3.5 million of common shares. The company plans to sell 729,241 shares in a PIPE financing, at $4.69 per share for investors and $5.21 per share for its Chief Executive Officer.
The closing is expected on June 15, 2026, subject to customary conditions. Edesa expects to use the net proceeds to advance its vitiligo program, its drug candidate paridiprubart, and for working capital and general corporate purposes. A Registration Rights Agreement requires Edesa to file one or more resale registration statements with the SEC within 45 days of closing.
Edesa Biotech reported new exploratory subgroup data for paridiprubart, its anti-TLR4 antibody, in critically ill patients with acute kidney injury and respiratory distress. Analyses pooling Phase 2 and Phase 3 studies created a 101-patient AKI subgroup from a broader 278-patient population with acute respiratory distress syndrome.
Paridiprubart plus standard of care was associated with adjusted 28-day mortality of 33% versus 49% for placebo, a 32% relative reduction in risk of death, and reduced major adverse kidney events (MAKE30) to 41% versus 53%, with nominal p<0.005 for both endpoints. Safety in the AKI subgroup remained consistent with more than 400 patients treated to date.
The company emphasizes that these AKI findings are exploratory, were not prespecified, use multivariate logistic regression, and are intended to generate hypotheses. Confirmatory studies would be required to establish efficacy in AKI, though the results support ongoing ARDS development and potential future AKI-focused trials.
Edesa Biotech, Inc. director and Chief Executive Officer Pardeep Nijhawan reported an equity compensation award in the form of restricted share units. He received 1,671 common shares at a price of $0.0000 per share, described as a grant or award acquisition.
The filing notes these restricted share units vested in full upon grant under the company’s 2019 Equity Incentive Compensation Plan. Following this award, Nijhawan directly holds 731,134 common shares, with additional indirect holdings reported through several related entities and a family trust, subject to customary beneficial ownership disclaimers.
Marshall Patrick reported acquisition or exercise transactions in this Form 4 filing.
Edesa Biotech director Patrick Marshall received a grant of 19,000 restricted share units at no cost under the company’s 2019 Equity Incentive Compensation Plan. These units vest in equal monthly installments over twelve months starting from the grant date. After this award, he holds 71,666 common shares directly and 465 shares indirectly through Quidnet Inc.
MacDonald Sean Arthur reported acquisition or exercise transactions in this Form 4 filing.
Edesa Biotech, Inc. reported that director Sean Arthur MacDonald received a grant of 19,000 restricted share units of Common Shares on May 27, 2026 at no cost, under the company’s 2019 Equity Incentive Compensation Plan. These units vest in equal portions over twelve months starting on the grant date. Following this award, MacDonald holds 41,054 Common Shares directly.
Chypyha Joan reported acquisition or exercise transactions in this Form 4 filing.
Edesa Biotech director Joan Chypyha received 19,000 common shares as a grant of restricted share units. The award was made at a stated price of $0.00 per share, reflecting compensation rather than an open-market purchase. Following this grant, Chypyha directly owns 30,029 common shares.
The restricted share units were issued under Edesa Biotech's 2019 Equity Incentive Compensation Plan and are scheduled to vest in equal portions over twelve months starting on the grant date. This represents a routine equity compensation award for a member of the board of directors.
Weiler Peter J. reported acquisition or exercise transactions in this Form 4 filing.
Edesa Biotech, Inc. reported that its Chief Financial Officer, Peter J. Weiler, received an equity grant in the form of restricted share units. He was awarded 64,609 Common Shares at a price of $0.00 per share as a compensation-related grant, not an open‑market purchase.
The grant was issued under the company’s 2019 Equity Incentive Compensation Plan and will vest monthly in equal portions over 36 months starting on the grant date. Following this award, Weiler directly holds 129,609 Common Shares, aligning a larger portion of his pay with the company’s future share performance.